If Bill Gates Turned to Philanthropy: Publicly Funded Clinical Drug Trials

High drug prices have been big news lately. Some of this has been due to straight out price gouging by the likes of Martin Shkreli, everyone's favorite young punk hedge fund tycoon and potential convict. However the more common problem stems from the exorbitant price charged for important new drugs like the Hepatitis C drug Solvaldi. Gilead Sciences, the patent holder for Solavldi, has a list price for this drug in the United States of $84,000 for a 3-month course of treatment. The company argue...